Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...